Dynamic changes of different phenotypic and genetic circulating tumor cells as a biomarker for evaluating the prognosis of RCC

References

• Barata PC, Rini BI. Treatment of renal cell carcinoma: current status and future directions. CA Cancer J Clin. 2017 Nov;67(6):507–524. doi:10.3322/caac.21411.
   PubMed Web of Science ®Google Scholar
• Siegel RL, Miller KD, Jemal A. Cancer Statistics, 2017. CA Cancer J Clin. 2017 Jan;67(1):7–30. doi:10.3322/caac.21387.
   PubMed Web of Science ®Google Scholar
• Choueiri TK, Motzer RJ. Systemic therapy for metastatic renal-cell carcinoma. N Engl J Med. 2017 Jan 26;376(4):354–366. doi:10.1056/NEJMra1601333.
   PubMed Web of Science ®Google Scholar
• Amin MB, Greene FL, Edge SB, Compton CC, Gershenwald JE, Brookland RK, Meyer L, Gress DM, Byrd DR, Winchester DP. The eighth edition AJCC cancer staging manual: continuing to build a bridge from a population-based to a more “personalized” approach to cancer staging. CA Cancer J Clin. 2017 Mar;67(2):93–99. doi:10.3322/caac.21388.
   PubMed Web of Science ®Google Scholar
• Janowitz T, Welsh SJ, Zaki K, Mulders P, Eisen T. Adjuvant therapy in renal cell carcinoma-past, present, and future. Semin Oncol. 2013 Aug;40(4):482–491. doi:10.1053/j.seminoncol.2013.05.004.
   PubMed Web of Science ®Google Scholar
• Harouaka R, Kang Z, Zheng SY, Cao L. Circulating tumor cells: advances in isolation and analysis, and challenges for clinical applications. Pharmacol Ther. 2014 Feb;141(2):209–221. doi:10.1016/j.pharmthera.2013.10.004.
   PubMed Web of Science ®Google Scholar
• Tseng JY, Yang CY, Liang SC, Liu RS, Jiang JK, Lin CH. Dynamic changes in numbers and properties of circulating tumor cells and their potential applications. Cancers. 2014 Dec 16;6(4):2369–2386. doi:10.3390/cancers6042369.
   PubMed Web of Science ®Google Scholar
• Jackson JM, Witek MA, Kamande JW, Soper SA. Materials and microfluidics: enabling the efficient isolation and analysis of circulating tumour cells. Chem Soc Rev. 2017 Jul 17;46(14):4245–4280. doi:10.1039/c7cs00016b.
   PubMed Web of Science ®Google Scholar
• Ankeny JS, Court CM, Hou S, Li Q, Song M, Wu D, Chen JF, Lee T, Lin M, Sho S, et al. Circulating tumour cells as a biomarker for diagnosis and staging in pancreatic cancer. Br J Cancer. 2016 Jun 14;114(12):1367–1375. doi:10.1038/bjc.2016.121.
   PubMed Web of Science ®Google Scholar
• Lambert AW, Pattabiraman DR, Weinberg RA. Emerging biological principles of metastasis. Cell. 2017 Feb 9;168(4):670–691. doi:10.1016/j.cell.2016.11.037.
   PubMed Web of Science ®Google Scholar
• Bluemke K, Bilkenroth U, Meye A, Fuessel S, Lautenschlaeger C, Goebel S, Melchior A, Heynemann H, Fornara P, Taubert H. Detection of circulating tumor cells in peripheral blood of patients with renal cell carcinoma correlates with prognosis. Cancer Epidemiol Biomarkers Prev. 2009 Aug;18(8):2190–2194. doi:10.1158/1055-9965.EPI-08-1178.
   PubMed Web of Science ®Google Scholar
• Nel I, Gauler TC, Bublitz K, Lazaridis L, Goergens A, Giebel B, Schuler M, Hoffmann A-C, Wu M-H. Circulating tumor cell composition in renal cell carcinoma. PloS one. 2016;11(4):e0153018. doi:10.1371/journal.pone.0153018.
   PubMed Web of Science ®Google Scholar
• Zhong Y, Wang QJ, Li X, Yan Y, Backer JM, Chait BT, Heintz N, Yue Z. Distinct regulation of autophagic activity by Atg14L and Rubicon associated with Beclin 1-phosphatidylinositol-3-kinase complex. Nat Cell Biol. 2009 Apr;11(4):468–476. doi:10.1038/ncb1854.
   PubMed Web of Science ®Google Scholar
• Nishikawa M, Miyake H, Liu B, Fujisawa M. Expression pattern of autophagy-related markers in non-metastatic clear cell renal cell carcinoma: association with disease recurrence following radical nephrectomy. J Cancer Res Clin Oncol. 2015 Sep;141(9):1585–1591. doi:10.1007/s00432-015-1923-4.
   PubMed Web of Science ®Google Scholar
• Motzer RJ, Jonasch E, Agarwal N, Beard C, Bhayani S, Bolger GB, Chang SS, Choueiri TK, Costello BA, Derweesh IH, et al. Kidney cancer, version 3.2015. J Natl Compr Cancer Network. 2015 Feb;13(2):151–159.
   PubMedGoogle Scholar
• Wu S, Liu S, Liu Z, Huang J, Pu X, Li J, Yang D, Deng H, Yang N, Xu J, et al. Classification of circulating tumor cells by epithelial-mesenchymal transition markers. PloS one. 2015;10(4):e0123976. doi:10.1371/journal.pone.0123976.
   PubMed Web of Science ®Google Scholar
• Tsongalis GJ. Branched DNA technology in molecular diagnostics. Am J Clin Pathol. 2006 Sep;126(3):448–453. doi:10.1309/90BU6KDXANFLN4RJ.
   PubMed Web of Science ®Google Scholar
• Perazella MA, Dreicer R, Rosner MH. Renal cell carcinoma for the nephrologist. Kidney Int. 2018 Apr 13;94:471–483. doi:10.1016/j.kint.2018.01.023.
   PubMed Web of Science ®Google Scholar
• Capitanio U, Montorsi F. Renal cancer. Lancet. 2016 Feb 27;387(10021):894–906. doi:10.1016/S0140-6736(15)00046-X.
   PubMed Web of Science ®Google Scholar
• Sunela KL, Lehtinen ET, Kataja MJ, Kujala PM, Soimakallio S, Kellokumpu-Lehtinen PL. Development of renal cell carcinoma (RCC) diagnostics and impact on prognosis. BJU Int. 2014 Feb;113(2):228–235. doi:10.1111/bju.12242.
   PubMed Web of Science ®Google Scholar
• Maertens Y, Humberg V, Erlmeier F, Steffens S, Steinestel J, Bögemann M, Schrader AJ, Bernemann C. Comparison of isolation platforms for detection of circulating renal cell carcinoma cells. Oncotarget. 2017 Oct 20;8(50):87710–87717. doi:10.18632/oncotarget.21197.
   PubMedGoogle Scholar
• Liu S, Tian Z, Zhang L, Hou S, Hu S, Wu J, Jing Y, Sun H, Yu F, Zhao L, et al. Combined cell surface carbonic anhydrase 9 and CD147 antigens enable high-efficiency capture of circulating tumor cells in clear cell renal cell carcinoma patients. Oncotarget. 2016 Sep 13;7(37):59877–59891. doi:10.18632/oncotarget.10979.
   PubMedGoogle Scholar
• Rossi E, Fassan M, Aieta M, Zilio F, Celadin R, Borin M, Grassi A, Troiani L, Basso U, Barile C, et al. Dynamic changes of live/apoptotic circulating tumour cells as predictive marker of response to sunitinib in metastatic renal cancer. Br J Cancer. 2012 Oct 9;107(8):1286–1294. doi:10.1038/bjc.2012.388.
   PubMed Web of Science ®Google Scholar
• Yang X, Bai F, Xu Y, Chen Y, Chen L. Intensified beclin-1 mediated by low expression of mir-30a-5p promotes chemoresistance in human small cell lung cancer. Cell Physiol Biochem. 2017;43(3):1126–1139. doi:10.1159/000481754.
   PubMed Web of Science ®Google Scholar
• Zheng B, Zhu H, Gu D, Pan X, Qian L, Xue B, Yang D, Zhou J, Shan Y. MiRNA-30a-mediated autophagy inhibition sensitizes renal cell carcinoma cells to sorafenib. Biochem Biophys Res Commun. 2015 Apr 3;459(2):234–239. doi:10.1016/j.bbrc.2015.02.084.
   PubMed Web of Science ®Google Scholar